阿托瓦斯塔丁在皮肤冠状动脉干预后对比诱导脏病患者的功能有效性
Heng Li1, Hongen Wang1, Siqi Ren1
1Department of Cardiology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, 215101, Jiangsu Province, China.
Journal of cardiothoracic surgery
|October 25, 2024
概括
高剂量的阿托瓦斯塔丁通过减少炎症和氧化应激,有效地保护经过皮肤冠状动脉干预 (PCI) 的患者的功能. 这种治疗是安全的,不会增加不良反应,使其成为预防对比诱导性病 (CIN) 的可行选择.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 预防和治疗对比诱导性病 (CIN) 的临床选择有限.
- 类他类药物在皮肤冠状动脉干预 (PCI) 等过程中显示出缓解CIN的潜力.
- 这项研究调查了阿托瓦斯塔丁在PCI后保留功能方面的疗效.
研究的目的:
- 评估高剂量阿托瓦斯塔丁在PCI后冠状动脉心脏病 (CHD) 患者对功能的影响.
- 为了比较高剂量和常规剂量阿托瓦斯塔丁组之间的功能指标,血液常规和不良反应.
主要方法:
- 一项涉及100名患有心脏病的老年患者接受PCI的研究.
- 患者被分为两组:一个实验组 (n=50) 接受每天40毫克阿托瓦斯塔丁,一个控制组 (n=50) 接受每天10毫克阿托瓦斯塔丁.
- 监测和比较功能指标,血液常规和不良反应.
主要成果:
- 高剂量阿托瓦斯塔丁组显示血清肌素,血尿素,囊素C,hs-CRP和IL-6的水平显著降低.
- 高剂量组表现出明显更高的估计膜过率和超氧化物脱酶水平.
- 这两组的不良反应发生率为8%,这表明安全性没有显著差异.
结论:
- 高剂量的阿托瓦斯塔丁 (每天40毫克) 有效地预防PCI后CIN患者的功能损伤.
- 高剂量的阿托瓦斯塔丁可降低这些患者的炎症和氧化应激.
- 该疗法显示出高效率和安全性,支持其在临床实践中的使用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:27Coronary Artery Disease V: Surgical Management
3
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
01:28Acute Coronary Syndrome IV: Interprofessional Care
3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3
01:28Imaging Studies for Cardiovascular System V: CT
3
Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
3
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
558
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
558
01:26Atherosclerosis III: Management
1
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
1